Briefing
NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening.
The primary endpoint, a reduction in stage III/IV incidence among 12 prespecified cancers, was not met (706 vs 688 events; IRR 1.03, 95% CI 0.92-1.14; P=0.6324). A 14% reduction in stage IV cancers was observed after 3 years (342 vs 397; overall IRR 0.86, 95% CI 0.744-0.998). Stage I/II cancers increased by 16% (RR 1.16) and stage I-III by 19% (RR 1.19). Screen-detected cancers were 1,173 vs 290. Aggregate specificity was 99.55% and PPV 52.0%. No related serious adverse events were reported.
- Design: LBA
- n: 142,924 enrolled participants in England, aged 50-79 years, randomized 1:1 after the year-0 blood draw
- Assay: Galleri MCED test (cfDNA cancer-signal test)